Low serum potassium levels and diabetes - An unfavorable combination in patients with heart failure and preserved ejection fraction

被引:5
作者
Eslam, Roza Badr [1 ]
Oeztuerk, Beguem [1 ]
Panzer, Simon [2 ]
Qin, Hong [1 ]
Duca, Franz [1 ]
Binder, Christina [1 ]
Rettl, Rene [1 ]
Dachs, Theresa Marie [1 ]
Alasti, Farideh [3 ]
Vila, Greisa [4 ]
Bonderman, Diana [1 ]
机构
[1] Med Univ Vienna, Div Cardiol, Vienna, Austria
[2] Med Univ Vienna, Div Blood Grp Serol & Transfus Med, Vienna, Austria
[3] Med Univ Vienna, Div Rheumatol, Vienna, Austria
[4] Med Univ Vienna, Div Endocrinol & Metab, Vienna, Austria
关键词
Heart failure with preserved ejection fraction; Serum potassium levels; Type-2 diabetes mellitus; ALDOSTERONE; TOPCAT; SPIRONOLACTONE; HYPOKALEMIA; MORTALITY; CORTISOL;
D O I
10.1016/j.ijcard.2020.04.029
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Heart failure with preserved ejection fraction (HFpEF) is among the most common forms of heart failure (HF). We aimed to investigate the prognostic significance of serum potassium levels and its interaction with type-2 diabetes mellitus in patients with HFpEF. Methods: Consecutive HFpEF patients were prospectively included in a registry study. The primary endpoint was a composite of cardiac death or HF hospitalization. Results: 363 HFpEF patients were enrolled (median age: 73.0 years; females: 70.3%). Median serum potassium (K +) was 4.3 mmol/L. A total of 128 (35.3%) patients had type-2 diabetes mellitus, of whom 92 were treated with oral anti-diabetic drugs and 35 with insulin. The study population was divided into two groups, according to their serum potassium levels. Significant differences between the groups were detected with regards to combined endpoint [n = 27 (61.4%) versus n = 87 (27.3%); p < 0.0001]. Lower serum potassium levels were significantly associated with adverse outcome in the Cox proportional hazard analysis [hazard ratio (HR): 1.83; 95% confidence interval (CI) 1.14-2.94; p = 0.0118]. Further independent predictors of adverse outcome were a history of HF hospitalizations (HR: 2.77; 95% CI 1.82-4.21; p < 0.0001), higher NT-pro BNP (HR: 1.93; 95% CI 1.82-4.21; p = 0.0084) as well as type-2 diabetes mellitus (HR: 1.57; 95% CI 1.05-2.34; p = 0.0027). Patients with diabetes and K+ <= 3.71 mmol/L faced the worst outcome as compared to the remainder of the group (p = 0.0001). Conclusion: In HFpEF patients, the combination of diabetes and low serum potassium levels are associated with an adverse outcome. (c) 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:121 / 127
页数:7
相关论文
共 33 条
[1]   Patients with HFpEF and HFrEF have different clinical characteristics but similar prognosis: a retrospective cohort study [J].
Abebe, Tamrat Befekadu ;
Gebreyohannes, Eyob Alemayehu ;
Tefera, Yonas Getaye ;
Abegaz, Tadesse Melaku .
BMC CARDIOVASCULAR DISORDERS, 2016, 16
[2]  
BONINI P, 1992, EUR J CLIN CHEM CLIN, V30, P881
[3]   Cardiomyocyte stiffness in Diastolic heart failure [J].
Borbély, A ;
van der Velden, J ;
Papp, Z ;
Bronzwaer, JGF ;
Edes, I ;
Stienen, GJM ;
Paulus, WJ .
CIRCULATION, 2005, 111 (06) :774-781
[4]   Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes [J].
Collins, Allan J. ;
Pitt, Bertram ;
Reaven, Nancy ;
Funk, Susan ;
McGaughey, Karen ;
Wilson, Daniel ;
Bushinsky, David A. .
AMERICAN JOURNAL OF NEPHROLOGY, 2017, 46 (03) :213-221
[5]   Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation [J].
de Denus, Simon ;
O'Meara, Eileen ;
Desai, Akshay S. ;
Claggett, Brian ;
Lewis, Eldrin F. ;
Leclair, Gregoire ;
Jutras, Martin ;
Lavoie, Joel ;
Solomon, Scott D. ;
Pitt, Bertram ;
Pfeffer, Marc A. ;
Rouleau, Jean L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (17) :1690-1692
[6]   Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial [J].
Desai, Akshay S. ;
Liu, Jiankang ;
Pfeffer, Marc A. ;
Claggett, Brian ;
Fleg, Jerome ;
Lewis, Eldrin F. ;
McKinlay, Sonja ;
O'Meara, Eileen ;
Shah, Sanjiv J. ;
Sweitzer, Nancy K. ;
Solomon, Scott ;
Pitt, Bertram .
JOURNAL OF CARDIAC FAILURE, 2018, 24 (05) :313-320
[7]   B-type natriuretic peptide increases cortisol and catecholamine concentrations in healthy subjects [J].
Grimm, Gabriele ;
Resl, Michael ;
Heinisch, Birgit B. ;
Huelsmann, Martin ;
Luger, Anton ;
Clodi, Martin ;
Vila, Greisa .
JOURNAL OF APPLIED PHYSIOLOGY, 2017, 122 (05) :1249-1254
[8]   Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure [J].
Gueder, Guelmisal ;
Bauersachs, Johann ;
Frantz, Stefan ;
Weismann, Dirk ;
Allolio, Bruno ;
Ertl, Georg ;
Angermann, Christiane E. ;
Stoerk, Stefan .
CIRCULATION, 2007, 115 (13) :1754-1761
[9]   N-terminal pro b-type natriuretic peptide (NT-pro-BNP) -based score can predict in-hospital mortality in patients with heart failure [J].
Huang, Ya-Ting ;
Tseng, Yuan-Teng ;
Chu, Tung-Wei ;
Chen, John ;
Lai, Min-Yu ;
Tang, Woung-Ru ;
Shiao, Chih-Chung .
SCIENTIFIC REPORTS, 2016, 6
[10]   Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity [J].
Jia, Guanghong ;
Hill, Michael A. ;
Sowers, James R. .
CIRCULATION RESEARCH, 2018, 122 (04) :624-638